Lancet: The trial of Lopinave-Litonave for new coronary pneumonia has failed.

Based on in vitro activity, preclinical studies and observational studies, Lopinavi-Litonavi is considered to be a treatable Covid-19.
recently, researchers reported the results of a randomized trial to assess the effects of Lopinavi-Litonavi on the prognostication of patients hospitalized with Covid-19.
the study, conducted at 176 health centres in the UK, compared a range of potential treatments with routine care for Covid-19 inpatients for randomized, controlled, open-label, platform trials.
patients receive 400mg of lopinave-100mg litonave treatment or a placebo on a routine basis, 10 days a month or until discharge.
of the study was a 28-day mortality rate.
study was conducted between 19 March and 29 June 2020, with 1,616 patients treated with Lopinave-Litonave and 3,424 patients receiving routine care only.
28 days, 374 patients in the Lopinave-Litonave treatment group died, and 767 patients in the general care group (23% vs. 22%, RR s 1.03) were consistent among the subgroups.
between the two groups (both 11 days) and the survival rate within 29 days (RR-0.98).
for patients who did not receive mechanical airfly at the baseline, there was no significant difference in the compound end points of mechanical air rate and mortality between groups (RR=1.09).
study found that for hospitalized patients with neo-coronary pneumonia, the treatment of Lopinave-Litonave did not reduce the risk of 28 days of mortality, hospital stay and mechanical aeration, and the results did not support the use of Lopinave-Litonave for the treatment of neo-coronary pneumonia.
.